GP
GPCR.US Structure Therapeutics Inc. American Depositary Shares
- Market cap
- USD 1.43B
- P/E
- -
- P/B
- 1.15x
- ROE
- -35.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is GPCR.US undervalued?
Graham numberThe Graham number of Structure Therapeutics Inc. American Depositary Shares cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Structure Therapeutics Inc. American Depositary Shares fundamental analysis
No fundamental analysis for Structure Therapeutics Inc. American Depositary Shares yet.
Structure Therapeutics Inc. American Depositary Shares stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Structure Therapeutics Inc. American Depositary Shares
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-…
Full company profileStructure Therapeutics Inc. American Depositary Shares financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Structure Therapeutics Inc. American Depositary Shares annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -20.0K | -266K | -623K | -949K | -2.60M | -3.90M | - |
| Operating Income | -15.9K | -37.7M | -52.6M | -103M | -158M | -288M | -486M |
| EBITDA | -15.9K | -37.6M | -52.3M | -75.7M | -121M | -139M | -434M |
| Net Income | -15.9K | -40.0M | -51.3M | -89.6M | -123M | -141M | -436M |
| EPS | 0.00 | -1.09 | -1.40 | -2.44 | -2.33 | -2.39 | -5.99 |
| Balance Sheet | |||||||
| Total Assets | 38.7M | 111M | 97.8M | 482M | 903M | 1.58B | 1.33B |
| Total Liabilities | 61.2M | 176M | 213M | 29.1M | 38.5M | 67.5M | 113M |
| Shareholders' Equity | -22.5M | -64.7M | -115M | 453M | 865M | 1.52B | 1.22B |
| Cash & Short-term Investments | 37.4M | 107M | 90.8M | 467M | 884M | 1.45B | 1.24B |
| Total Debt | 280K | 621K | 260K | 5.45M | 3.86M | 6.49M | 6.83M |
| Cash Flow | |||||||
| Operating Cash Flow | -14.3M | -32.2M | -46.1M | -79.5M | -117M | -222M | -275M |
| Capital Expenditure | 19.0K | 1.21M | 155K | 2.17M | 1.29M | 3.61M | 6.50M |
| Free Cash Flow | -14.3M | -33.4M | -46.3M | -81.7M | -118M | -226M | -282M |
| Ratios | |||||||
| ROE | - | - | - | -19.8% | -14.2% | -9.3% | -35.7% |
| ROA | 0.0% | -36.0% | -52.5% | -18.6% | -13.6% | -8.9% | -32.7% |
| Debt to Equity | - | - | - | 0.01x | 0.00x | 0.00x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Structure Therapeutics Inc. American Depositary Shares dividends
Structure Therapeutics Inc. American Depositary Shares has not paid dividends in the last 6 fiscal years.
Who owns Structure Therapeutics Inc. American Depositary Shares
- Insiders 3.11%
- Institutions 96.32%
- Public & others 0.58%
- Shares outstanding 71.3M
- Free float 55.5M
Top funds holding GPCR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Health Care Inv | 4.42M | 6.19% | +51.78% | Sep 2026 |
| Worldwide Healthcare Ord | 1.31M | 1.84% | 0.00% | Jul 2026 |
| Fidelity Advisor Growth Opps M | 734K | 1.03% | 0.00% | Sep 2026 |
| Fidelity Advisor Biotechnology I | 664K | 0.93% | +25.69% | Sep 2026 |
| Principal Glb Emerging Markets R5 | 626K | 0.88% | 0.00% | Sep 2026 |
| Fidelity VIP Contrafund Initial | 584K | 0.82% | -1.79% | Sep 2026 |
| Janus Henderson Hrzn Biotec E2 USD | 581K | 0.82% | +2.84% | Jun 2026 |
| Janus Global Life Science AUSD | 549K | 0.77% | +2.79% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 546K | 0.77% | +186.23% | Sep 2026 |
| Fidelity Select Biotechnology | 542K | 0.76% | 0.00% | Aug 2026 |
| Janus Henderson Glb Life Scn I2 USD | 540K | 0.76% | +1.46% | Aug 2026 |
| Fidelity Advisor New Insights I | 530K | 0.74% | -1.73% | Sep 2026 |
| Fidelity Select Health Care | 500K | 0.70% | 0.00% | Aug 2026 |
| iShares Biotechnology ETF | 481K | 0.67% | -0.19% | Oct 2026 |
| Janus Henderson Triton D | 467K | 0.66% | 0.00% | Sep 2026 |
| Fidelity Stock Selector Small Cap | 459K | 0.64% | +6.05% | Aug 2026 |
| Janus Henderson Global Life Sciences D | 446K | 0.63% | -20.49% | Sep 2026 |
| Fidelity Small Cap Growth | 414K | 0.58% | 0.00% | Aug 2026 |
| Vanguard Explorer Inv | 406K | 0.57% | 0.00% | Sep 2026 |
| Permanent Portfolio Permanent I | 400K | 0.56% | 0.00% | Oct 2026 |
Top institutions holding GPCR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 7.81M | 10.95% | -7.06% | Jun 2026 |
| Wellington Management Company LLP | 7.38M | 10.35% | +1.64% | Jun 2026 |
| venBio Select Advisor LLC | 6.56M | 9.19% | 0.00% | Jun 2026 |
| Jupiter Topco LLC | 5.20M | 7.30% | 0.00% | Jun 2026 |
| Deep Track Capital, LP | 4.74M | 6.65% | +10.75% | Jun 2026 |
| Bvf Inc | 3.37M | 4.72% | -2.67% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.81M | 3.94% | +21.74% | Jun 2026 |
| Orbimed Advisors LLC | 2.21M | 3.10% | +49.75% | Jun 2026 |
| American Century Companies Inc | 1.68M | 2.36% | +16.98% | Jun 2026 |
| RTW INVESTMENTS, LLC | 1.61M | 2.25% | 0.00% | Jun 2026 |
| Driehaus Capital Management LLC | 1.55M | 2.18% | -1.53% | Jun 2026 |
| Baker Bros Advisors LP | 1.43M | 2.01% | 0.00% | Jun 2026 |
| Principal Financial Group Inc | 1.26M | 1.77% | -27.83% | Sep 2026 |
| Casdin Capital, LLC | 1.18M | 1.65% | 0.00% | Jun 2026 |
| Deerfield Management Co | 1.09M | 1.52% | +41.41% | Jun 2026 |
| Capitolis Liquid Global Markets LLC | 1.04M | 1.46% | -9.57% | Jun 2026 |
| Siren, L.L.C. | 873K | 1.22% | -34.30% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 846K | 1.19% | -57.74% | Jun 2026 |
| Pacific Heights Asset Management, LLC | 800K | 1.12% | 0.00% | Sep 2026 |
| Rock Springs Capital Management LP | 640K | 0.90% | +0.02% | Jun 2026 |
Structure Therapeutics Inc. American Depositary Shares company profile
- Company name
- Structure Therapeutics Inc. American Depositary Shares
- Ticker
- GPCR.US
- Exchange
- USA Stocks
- Listed since
- Feb 3, 2023
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 281
- Fiscal year end
- December
- Address
- 601 Gateway Boulevard, South San Francisco, CA, United States, 94080
- Phone
- 650 457 1978
- Website
- structuretx.com
About Structure Therapeutics Inc. American Depositary Shares
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Structure Therapeutics Inc. American Depositary Shares management
10- Dr. Raymond C. Stevens Ph.D.CEO & Director · born 1964
- Mr. Jun S. YoonCo- Founder, CFO & Secretary · born 1978
- Dr. Yingli Ma Ph.D.Chief Technology Officer · born 1974
- Dr. Xichen Lin Ph.D.Chief Scientific Officer & GM of Structure Shanghai · born 1974
- Dr. Blai Coll M.D., Ph.D.Chief Medical Officer · born 1974
- Mr. Matthew Lang J.D.COO & General Counsel · born 1976
- Mr. Bob GatmaitanSenior Vice President of People
- Dr. Hui Lei Ph.D.Senior Vice President of Chemistry
- Dr. Fang Zhang Ph.D.Executive VP & Head of Biology
- Ms. Lani IbarraSenior Vice President of Clinical Development Operations